BACKGROUND/AIMS: A phase I clinical trial has been planned to determine the recommended dose and to assess the safety and efficacy of combination chemotherapy of @entity11730 with @entity900 and @entity2600 (SCI regimen) as a second-line treatment in @entity1487 ( @entity1487 ) resistant @entity14 ( @entity14 ). METHODOLOGY: @entity1 with unresectable recurrent or metastatic @entity14 were enrolled in this study for second-line treatment. On an outpatient basis, the @entity1 received a treatment SCI regimen comprising @entity11730 oral administration for 28 days followed by withdrawal for 2 weeks, plus @entity900 and @entity2600 were administered on days 1, 8, 15 and 22 by intravenous injection. These courses were repeated every 6 weeks. Starting doses were 70 mg/m2 @entity11730 , 6 mg/m2 @entity900 , and 60 mg/m2 @entity2600 . RESULTS: A total of 29 @entity1 was enrolled. Dose-limiting @entity137 were @entity1295 , @entity390 , and @entity1210 . Twenty-three @entity1 at recommended dose were evaluable for treatment response. The response rate was 21.7% (5 partial responses, 13 stable diseases, and 5 progressive diseases). The median progression-free survival rate was 4.3 months; the median survival time was 9.6 months. CONCLUSIONS: The SCI regimen is feasible in an outpatient setting and should be considered as second-line chemotherapy for @entity1 with @entity1487 resistant @entity14 .

Second-line combination chemotherapy of oral @entity11730 with @entity900 and @entity2600 for XXXX resistant to @entity1487 .

@entity1 :: ('9606', 'Species') :: ['Patients', 'patients'] @entity137 :: ('MESH:D064420', 'Disease') :: ['toxicities'] @entity2600 :: ('MESH:C051890', 'Chemical') :: ['Irinotecan', 'irinotecan'] @entity390 :: ('MESH:D009325', 'Disease') :: ['nausea'] @entity11730 :: ('5707', 'Gene') :: ['S-1'] @entity900 :: ('MESH:D002945', 'Chemical') :: ['cisplatin', 'Cisplatin'] @entity1295 :: ('MESH:D005221', 'Disease') :: ['fatigue'] @entity14 :: ('MESH:D015179', 'Disease') :: ['CRC', 'colorectal cancer'] @entity1487 :: ('MESH:D005472', 'Chemical') :: ['5-FU', '5-fluorouracil'] @entity1210 :: ('MESH:C536227', 'Disease') :: ['leucopenia']
@entity14 :: (MESH:D015179,Disease) :: ['colorectal cancer']
